Related Experiment Video

Updated: Jun 19, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Antivascular agents for non-small-cell lung cancer: current status and future directions

Eitan Amir1, Laszlo Mandoky, Fiona Blackhall

  • 1Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, UK.

Expert Opinion on Investigational Drugs
|November 3, 2009
PubMed
Abstract

Insights

Antivascular therapies, like bevacizumab targeting vascular endothelial growth factor (VEGF), offer improved survival for non-small-cell lung cancer (NSCLC) patients. Ongoing research explores new antivascular agents for advanced NSCLC treatment.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Non-small-cell lung cancer (NSCLC) treatment has seen modest advances, but survival remains poor.
  • Targeted therapies, particularly antivascular drugs, are a focus for improving NSCLC outcomes.

Purpose of the Study:

  • To review current knowledge on antivascular therapy for non-small-cell lung cancer (NSCLC).

Main Methods:

  • A review of randomized controlled trials (RCTs) investigating antivascular drugs in NSCLC patients.

Main Results:

  • Bevacizumab, an anti-VEGF antibody, was the first treatment to extend overall survival beyond 12 months in advanced NSCLC when combined with chemotherapy.
  • Investigational antivascular strategies including small-molecule tyrosine kinase inhibitors, VEGF-trap, and vascular disrupting agents show promise.

Conclusions:

  • Antivascular agents represent a significant breakthrough in managing advanced NSCLC.
  • Bevacizumab plus chemotherapy offers improved overall survival for advanced NSCLC patients.
  • Further investigation into novel antivascular agents is warranted for NSCLC treatment.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...